Key Developments: Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.14USD
3:32pm EDT
Change (% chg)

$-0.00 (-1.79%)
Prev Close
$0.14
Open
$0.14
Day's High
$0.14
Day's Low
$0.14
Volume
1,012
Avg. Vol
50,315
52-wk High
$0.46
52-wk Low
$0.05

Search Stocks

Latest Key Developments (Source: Significant Developments)

Interleukin Genetics appoints Mark B. Carbeau as CEO
Tuesday, 7 Apr 2015 08:00am EDT 

Interleukin Genetics Inc:Appoints Mark B. Carbeau as Chief Executive Officer and Director.Says Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.  Full Article

Interleukin Genetics expands its collaboration with Isis Pharmaceuticals for Genetic Testing Services
Monday, 9 Mar 2015 08:00am EDT 

Interleukin Genetics Inc:Announced that under the terms of its collaboration agreement with Isis Pharmaceuticals.Says the Company will provide Isis with testing kits and will prepare DNA, run genotypes and provide data for SNP genotypes for the IL-1 and LP(a) SNPs for Isis' Phase 1 clinical study evaluating its novel therapeutic, ISIS-APO(a)-LRxin healthy volunteers with elevated lipoprotein.Lp is an independent risk factor for cardiovascular disease.Says this Phase I study is the second Isis clinical study to incorporate Interleukin's genetic test into the trial design to add genetic information at the earliest phases of testing of their new product lines.  Full Article

Interleukin Genetics announces collaboration with Isis Pharmaceuticals for genetic testing services
Wednesday, 7 Jan 2015 08:00am EST 

Interleukin Genetics Inc:Says an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.  Full Article

Interleukin Genetics Inc announces appointment of interim chief financial officer - Form 8-K
Wednesday, 10 Sep 2014 04:07pm EDT 

Interleukin Genetics Inc:Appoints Stephen DiPalma, managing director of Danforth, as interim chief financial officer.Says DiPalma replaces Eliot Lurier, who resigned as chief financial officer of the company effective as of the close of business on Sept. 5, 2014.  Full Article

Interleukin Genetics Inc announces resignation of CFO -Form 8-K
Monday, 25 Aug 2014 04:08pm EDT 

Interleukin Genetics Inc:Says on Aug. 21, 2014, Eliot M. Lurier, the chief financial officer, informed the company that he was resigning in order to pursue another professional opportunity at a Boston-based academic institution with which he has had a long standing personal relationship.Says Lurier’s resignation will be effective as of the close of business on Sept. 5.  Full Article

Interleukin Genetics Inc secures approval in New York State to offer PerioPredict
Tuesday, 22 Apr 2014 07:00am EDT 

Interleukin Genetics Inc:Receives conditional approval from New York State Department of Health to offer, process and report results of PerioPredict Genetic Risk Test for periodontal disease.State of New York is the only U.S. state that requires an independent regulatory review process including technical validation with clinical utility for laboratory developed tests run within a CLIA certified laboratory.As result of New York State approval the PerioPredict test is available to dental providers and their patients in all 50 U.S. states.  Full Article

Interleukin Genetics Inc Announces $12 Million Private Placement
Monday, 20 May 2013 07:55am EDT 

Interleukin Genetics Inc announced that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share and issued warrants to purchase an aggregate of 32,786,885 shares of common stock at an exercise price of $0.2745 per share to the investors. Subject to future approval by Interleukin`s shareholders of an increase in the number of authorized shares of common stock, each investor has the right, prior to June 30, 2014, to purchase its pro rata share of up to an aggregate of $5,000,000 of additional shares of common stock and warrants on the same terms and conditions as those set forth above. Immediately prior to the closing of this transaction Pyxis Innovations Inc., the sole holder of Interleukin`s Series A-1 Preferred Stock, converted all outstanding shares of Series A-1 Preferred Stock into 28,160,200 shares of common stock and converted all of Interleukin`s outstanding convertible debt ($14,316,255) into 2,521,222 shares of common stock. BTIG, LLC acted as the exclusive placement agent for the transaction.  Full Article

Search Stocks